Evidence map›Paper›PMID 27067436›Full record

ArticleMedical oncology (Northwood, London, England)2016

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.

Daniel A Goldstein, Kavya Krishna, Christopher R Flowers, Bassel F El-Rayes, Tanios Bekaii-Saab, Anne M Noonan

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Cancer drug development: The missing links.Experimental biology and medicine (Maywood, N.J.) · 2019
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Daniel A GoldsteinDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Kavya KrishnaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, A445 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH, 43210, USA.
Christopher R FlowersDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Bassel F El-RayesDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Tanios Bekaii-SaabDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, A445 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH, 43210, USA.
Anne M NoonanDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, A445 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH, 43210, USA. anne.noonan@osumc.edu.
Emory University · USThe Ohio State University · US

Funding

NCI NIH HHS T32CA160040-02
6 · The paper itself

Abstract

Multiple chemotherapy regimens are available for the treatment of metastatic pancreas cancer (mPCA). Choice of regimen is based on the patient's performance status and toxicity profile of the regimen. The objective of this study was to analyze the costs of first-line regimens to further aid in decision-making and develop a platform upon which to assess value. We calculated the monthly cost for individual standard regimens (gemcitabine, gemcitabine/nab-paclitaxel, gemcitabine/erlotinib and FOLFIRINOX) and the overall treatment cost for a course of therapy based on the median progression-free survival achieved in published studies. In addition to cost of drugs, we included administration costs and costs of toxicities (including growth factor support, blood product transfusion and hospitalization for toxicities). Costs for administration and management of adverse events were based on Medicare reimbursement rates for hospital and physician services. Drug costs were based on Medicare average sale prices (all 2014 US$). The monthly costs for gemcitabine, FOLFIRINOX, gemcitabine/erlotinib and gemcitabine/nab-paclitaxel were $1363, $7234, $8007 and $12,221, respectively. The overall treatment costs for a course of the same regimens based on median PFS were $5043, $46,298, $51,004 and $67,216, respectively. The choice of chemotherapy regimen for mPCA should be based on tolerability and efficacy of the regimen individualized to patient's performance status. Healthcare systems have finite resources; thus, there is increasing emphasis on metrics to define value in health care when outcomes of therapy are similar or produce marked differences in value. These data provide useful financial information to incorporate into the decision-making process.

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisCosts and Cost AnalysisDeoxycytidineGemcitabineHumansPaclitaxelPancreatic Neoplasms130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabinePaclitaxelChemotherapy costsFirst-line regimensMetastatic pancreas cancerToxicity costsValue

Identifiers

PMID27067436
OpenAlexW2340641404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.